Open in interactive viewer → charts, metric popovers & call review

Anaergia Sold Its Way to a Profit. Now It Has to Earn One.

A $21.9 million gain on two divested plants turned Q3 net income positive — but the durable story is a $303 million backlog, a 1.48 book-to-bill, and a fifth straight positive EBITDA quarter.
ANRG.TO · Earnings Call · 2026-11-12

The quarter Anaergia stopped apologizing for two plants

For at least a year, Anaergia's story had a hole in it called Rhode Island. On the August call, asked whether the RIB facility would reach breakeven in the back half of the year and ramp toward 80% utilization, COO Yaniv Scherson declined to commit:

We continue to deal with technical issues at the site and the site is improving year-over-year. However, at this point, we're unable to give any predictions or guidance as to timeline for breakeven. As mentioned, we're exploring options that are best suited for the asset. It has underperformed.

Yaniv Scherson, Unknown · 2026-08-11
Three months later, the "option" turned out to be the exit door. At the end of September, Anaergia sold 100% of its interest in the Rhode Island Bioenergy facility and the project assets of Charlotte Bioenergy. The transaction booked a $21.9 million gain, pushed a USD 20 million East West Bank term loan onto the purchaser, and left Anaergia holding a stake in the buyer so shareholders retain upside on assets management had already written off operationally. The company's own keyword table tells the story in four entries: the Rhode Island divestiture, the Charlotte facility exit, plus negative earnings and project level debt as the things being removed.

In my judgment, those 2 facilities were underperforming, generating negative earnings and absorbing capital and management attention. So we sold them. The transaction recognized a $21.9 million gain, removed project-level debt from our balance sheet, eliminated the negative earnings, and we secured a stake in the buyer.

Assaf Onn, Chief Executive Officer · 2026-11-12
Note the direction of travel. On the prior call, an analyst asked about buying biomethane assets as M&A heated up; the answer was that the company was "always scanning the market" with “nothing to say more at this point” — Assaf Onn, Chief Executive Officer · 2026-08-11. A quarter later, the first big balance-sheet decision under this CEO was subtraction, not addition. That is a genuine change in posture, and it reframes the remaining build-own-operate book around three profitable facilities — SoCal Biomethane, Escondido and Mojave.

Reading past the gain

Strip out the one-time gain and the quarter still advances. Revenue was $66.9 million, up 30.3% year over year; nine-month revenue of $186 million rose 71.5% and already exceeds all of fiscal 2025. Gross profit of $16.4 million was up 11%, and adjusted EBITDA of $3.1 million marked a fifth consecutive positive quarter. Year to date, adjusted EBITDA swung from a $3.6 million loss to $6.1 million of profit — a $9.7 million improvement — with trailing-twelve-month adjusted EBITDA around $10.3 million. Against a market capitalization near $213 million, that is roughly 21x trailing EBITDA: not a distressed multiple, which means the backlog has to convert for the stock to make sense. The wrinkle is margin optics. Reported Q3 gross margin of 24.5% looks like a 430 basis point collapse against 28.8% a year ago — but that comparison carries the operating cost of two facilities that management had already decided to sell, straight through to the September 29 close. Adjusted for the divestitures, gross profit would have been about $1.5 million higher in the quarter and roughly 2.9 percentage points better on margin; for the nine months, about 27.1%. Both numbers are true; only one is forward-looking. The genuinely encouraging line is cost. Nine-month SG&A of $45 million came in 0.9% below the prior year while revenue grew 71.5%. CFO Gregory Wolf attributes part of the quarter's $15.7 million SG&A to higher labor and legal reserves, so the leverage is a year-to-date phenomenon rather than a Q3 one — worth flagging, because it means the operating-leverage claim rests on a lumpy sequence. Scherson's explanation for why it should hold is the more important piece of the thesis: “the majority of the work that we need to scale is billed to the project, embedded in the cost, mostly billable labor” — Yaniv Scherson, Chief Operating Officer · 2026-11-12. Growth without proportional overhead, in other words, as long as the regional-base model works.

Two countries in three months

That model is the actual strategic claim of this call. Anaergia's revenue engine this quarter was Italy and North America — “Our large projects in Italy and North America are proceeding normal course” — Yaniv Scherson, Chief Operating Officer · 2026-11-12 — and the new news is what those hubs spawned. From the Italian base came a $36 million agreement with Hungary's TisVet and a second ~$34 million EPC contract for a renewable natural gas facility, together opening Hungary as a market. From the Singapore base came the first Australian reference plant with RF Corval, roughly $14 million, at Goodness Grown's Tongala site. Two new countries in three months, both fed by existing regional base teams rather than new corporate overhead. The booking math followed: about $86 million of new awards in Q3, a book-to-bill of 1.48 on capital sales, and revenue backlog of $303.1 million — up 10.3% sequentially and 18.2% from year-end 2025. “we booked roughly 48% more capital sale contracts than we recognized as revenue during the quarter” — Gregory Wolf, Chief Financial Officer · 2026-11-12. The caveat a good analyst would raise, and one did: the $34 million Hungary EPC was press-released on November 9 but “booked on September 30 in Q3” — Assaf Onn, Chief Executive Officer · 2026-11-12. A last-day booking in a lumpy project business is exactly the kind of thing that flatters a book-to-bill ratio. Management's forward answer was unhedged: “We are more confident than ever that we will be much higher than we are today” — Assaf Onn, Chief Executive Officer · 2026-11-12 on capital sales backlog by year end.

What replaced "loss of CAD"

The most telling thing in the company's keyword history is an absence. Last quarter, loss of CAD sat near the top of Anaergia's theme list — the net-loss language that had defined the equity story. It is gone, replaced by profitable growth, renewable natural gas, and centers of excellence. Also noticeably quieter: the Vanguard Renewables contract and the Ameresco joint venture, both of which were prominent a quarter ago. The narrative has narrowed to fewer, better assets. What has not changed is the dependence on policy. Scherson ticks through Italy's Recovery and Resilience Plan, the REPowerEU biomethane target, the UK Green Gas Support Scheme, Canada's Clean Fuel Regulations, and California's SB 1440 offtake underpinning SoCal Biomethane. This is a market-wide trade, not just an Anaergia one — the global keyword set this quarter carries 45Z value in its top-75, with several recent reporters in renewable fuels leaning on credit economics. Anaergia sits inside that policy cycle, but its nearer catalyst is operational: SoCal is still ramping into a larger contracted volume, with “over the coming quarters into next year, we'll be approaching the nameplate” — Yaniv Scherson, Chief Operating Officer · 2026-11-12. The bull case, then, is straightforward. Capital sales convert a $303 million backlog, O&M and service layer on top of every plant built — conservatively counted at only three years of contracts that typically run five to fifteen — and SG&A stays flat. The bear case is that margins, not revenue, are the constraint: nine-month gross margin of 23.4% against 28.3% a year ago, a $4.5 million CapEx quarter the CFO calls elevated, and a company that has now cleared its problem assets but must prove the remaining three can run at nameplate. Management had a point last quarter when it said it saw few constraints to “double the revenues here” — Gregory Wolf, Chief Financial Officer · 2026-08-11. This quarter it finally has the backlog to test that claim.